Introduction {#s02}
============

Reactive oxygen species (ROS; H~2~O~2~, O~2~-, OH-, etc.) are produced by aerobic cells under physiological conditions. These compounds, when produced in larger quantities under stress, can lead to extensive damage of DNA, proteins, and plasma/organelle membranes in the cell ([@bib49]; [@bib3]; [@bib58]). Multiple repair mechanisms remove DNA lesions and ultimately degrade misfolded proteins ([@bib3]; [@bib58]). However, ROS production is significantly increased in cancer cells because of mitochondrial dysfunction, altered metabolism, and frequent genetic mutations, resulting in an accumulation of large amounts of oxidized protein, DNA, and lipids ([@bib11]). Therefore, as an adaptive response, cancer cells harbor elevated levels of ROS-scavenging molecules. Antioxidant mechanisms include enhanced expression of molecules that can modulate ROS accumulation by both enzymatic and nonenzymatic means ([@bib64]; [@bib22]). Enzymatic antioxidant responses include increased abundance of superoxide dismutase or catalase ([@bib60]; [@bib27]; [@bib68]). In addition, other small redox protein-encoding genes that generate thioredoxins, heme oxygenases, and peroxiredoxins are also stimulated ([@bib60]).

Glutathione (GSH) is an antioxidant that acts as a free radical scavenger and a detoxifying agent in cells. It is useful in a multitude of processes, cellular proliferation, cell division, and differentiation, and is the most commonly elevated metabolite detected during oxidative stress. Under physiological conditions, reduced GSH is the major form present with a concentration 10- to 100-fold higher than the oxidized species (GSH disulfide \[GSSG\]). Under oxidative stress, GSH is converted by GSH-dependent peroxidases into GSSG upon its reaction with ROS. GSH is synthesized in the cytosol and further distributed to different organelles. Apart from the classical antioxidant role, GSH also has several organelle-specific functions discussed in detail by [@bib46]. More than 10% of the synthesized GSH is found in mitochondria, where it reacts with ROS and prevents apoptosis. A highly reducing environment is maintained in subcellular compartments, e.g., the cytosol, nucleus, mitochondrial matrix, and peroxisome, to facilitate proper protein folding and activity. In contrast, the ER maintains a highly oxidized environment and increased levels of GSSG. This supports the functional conformation of peptides, especially for the addition of disulfide bonds to the nascent secretory and membrane proteins. Additionally, a high GSH/GSSG ratio in the nucleus ensures synthesis of deoxyribonucleotides from ribonucleotides and maintenance of sulfhydryl groups in proteins for proper nucleic acid biosynthesis and DNA repair. This ratio in each organelle also reflects the metabolic pathways and resulting oxidative burdens that they face throughout phases of cell growth. Furthermore, GSH is involved in (a) detoxification of xenobiotics, (b) maintenance of cysteine pools, (c) maturation of iron--sulfur clusters of diverse proteins, and (d) regulation of transcription factors related to redox signaling ([@bib13]; [@bib65]). GSH helps maintain protein sulfhydryl groups in a reduced form by supporting a balance of thiol redox potential in cells. As a result, disturbances in GSH homeostasis are often found in multiple pathologies, e.g., neurodegenerative disorders, cancer, cystic fibrosis, liver disorders, and diabetes ([@bib14]).

With respect to cancer, GSH plays a dual role in its progression. It is crucial in the removal and detoxification of carcinogens, and alterations in this pathway can have a profound effect on cell survival. However, elevated levels of GSH in tumor cells are able to protect such cells in bone marrow, breast, colon, larynx, and lung cancers by conferring resistance to several chemotherapeutic drugs ([@bib69]; [@bib42]). The effect of GSH on oxidative stress and cancer initiation and progression is also complicated because of the dual role of ROS in these processes. Moderate ROS levels can support survival and proliferation by activating signaling pathways that can contribute to tumor growth in stressful tumor microenvironments ([Fig. 1](#fig1){ref-type="fig"}). However, excessive ROS accumulation, failure of proper scavenging mechanisms, or antioxidant scarcity results in severe damage of biomolecules, triggering cell death. Therefore, cancer cells need to maintain an intricate balance of antioxidant levels to survive. Additionally, ROS are able to regulate the potential of cancer cells to metastasize to distant locations. Data supporting this indicated that elevated GSH promotes metastasis in both melanoma and liver cancer ([@bib7]; [@bib26]). In addition to GSH, other common antioxidants, *N*-acetyl cysteine (NAC) and the vitamin E analogue trolox, promote distant metastasis ([@bib7]; [@bib26]; [@bib55]). These data emphasize the dual roles of ROS and GSH in cancer initiation and progression ([@bib16]).

![**Maintenance of redox homeostasis in normal versus cancer cells. (A)** Cells maintain a balance of antioxidants against ROS generated by the different physiological processes. **(B)** Cellular ([@bib37]) redox states are maintained by modulating ROS production and elimination. Under normal conditions, cells maintain homeostasis by producing enough antioxidants to balance ROS production. However, because of hypoxia and metabolic alterations in cancer cells, increased amounts of ROS are generated, which are counteracted by enhanced antioxidant responses. However, when this balance is disrupted, high ROS levels can disrupt normal cellular machinery, triggering cell death.](JCB_201804161_Fig1){#fig1}

GSH synthetic enzymes involved in tumor progression {#s03}
===================================================

GSH is the most prevalent nonprotein thiol in eukaryotic cells and exists in both thiol-reduced (GSH) and disulfide-oxidized (GSSG) forms ([@bib32]). GSH is the predominant form, existing in millimolar concentrations in most cells (liver 5--10 mM; [@bib69]). This tripeptide is produced by de novo biosynthesis involving a two-step, ATP-dependent enzymatic reaction ([Fig. 2](#fig2){ref-type="fig"}). The first is catalyzed by glutamate cysteine ligase (GCL), which ligates cysteine to glutamate to produce γ-glutamylcysteine. This dipeptide is then combined with glycine by GSH synthetase (GSS) to produce GSH ([@bib42]). Besides the synthetic pathway described above, cells can convert GSSG to GSH ([@bib43]) catalyzed by GSH reductase, which requires NADPH as a substrate and thus links NADPH levels directly to GSH synthesis. Therefore, high GSH/GSSG ratios in cancer cells can also be explained by increased flux through the pentose phosphate pathway (PPP), which produces NADPH ([@bib37]; [@bib76]). Consistent with increased PPP flux, clear cell renal cell carcinoma (ccRCC) tumors display significant accumulation of reduced GSH and PPP-related metabolites ([@bib37]).

![**De novo biosynthesis of GSH.** GSH is generated from glutamic acid, cysteine, and glycine in two successive ATP-dependent enzymatic steps. First, γ-glutamylcysteine is synthesized by a GCL, a reaction consuming glutamic acid and cysteine, and forming a γ-peptide bond. The second step is catalyzed by GSS, adding glycine to the C terminus of γ-glutamylcysteine, resulting in the final GSH product.](JCB_201804161_Fig2){#fig2}

Regulation of GSH levels in the cells {#s04}
=====================================

Under physiological conditions, GCL expression, its enzymatic activity, and cysteine abundance constitute rate-limiting steps for GSH synthesis ([@bib42], [@bib43]). GCL levels are controlled by the nuclear factor erythroid 2--related factor 2 (NRF2) transcription factor (discussed in more detail later in this review). GCL is a heterodimer consisting of a 73-kD catalytic subunit (GCLC) and 31-kD modulatory subunit (GCLM; [@bib12]; [@bib5]; [@bib42]). *GCLM* null mutant mice have \<25% of cellular GSH yet are surprisingly viable. In contrast, high GCLM expression has been found to be associated with therapeutic resistance in breast cancer ([@bib42]). Additionally, *GCLM* mutations result in delayed tumor onset in sarcoma, mammary, and lymphoma mouse models ([@bib15]; [@bib42]), making GCLM an effective pharmacologic target to combat chemotherapeutic resistance in these cancers. Under physiological conditions, the GCLC/GCLM heterodimer is regulated by feedback inhibition by its product GSH ([@bib42]). However, under oxidative stress or disease conditions, GCL levels increase because of the action of several nuclear transcription factors: NRF2--Kelch-like ECH-associated protein 1 (KEAP1) and NFκB ([@bib21]; [@bib43]). *GCL* deficiency is a rare autosomal disease characterized by reduced GSH, hemolytic anemia, and neurological symptoms ([@bib48]; [@bib53]). High GCLC levels are found in patients suffering from melanoma and lung cancer ([@bib15]). Moreover, increased GCLC enzymatic activity has been detected in renal cell carcinoma patients ([@bib38]). GCLC expression is attenuated by Myc-induced *miR-18a*, and these tumors are highly susceptible to oxidative stress ([@bib4]). Myc also regulates *GCLC* expression in effector T cells, which can modulate immunotherapeutic responses in cancer patients ([@bib50]). Reduction of GSH production by the irreversible GCL inhibitor buthionine sulfoxime (BSO) promotes apoptosis in breast and ovarian cancer cells and attenuates cell growth in esophageal cancer ([@bib5]). Combinatorial therapy with BSO is being used in clinical trials to determine whether patients respond better to melphalan in resistant neuroblastoma patients ([@bib66]; [@bib4]).

The enzyme GSS, involved in catalyzing the second step of de novo GSH biosynthesis, is not regulated by feedback inhibition by GSH. However, GSS activity is also important in certain disease conditions where an inactive enzyme results in γ-glutamylcysteine accumulation ([Fig. 2](#fig2){ref-type="fig"}). This intermediate can be converted to 5-oxoproline by γ-glutamylcyclotransferase and cause severe hemolytic anemia, metabolic acidosis, and central nervous system damage ([@bib57]). Additionally, although increased GSS and GCLC are found in colon cancer patients ([@bib34]), GSS variants are also correlated with the recurrence of bladder cancer and small cell lung cancer ([@bib33]). However, roles of GSS in cancers have not been studied in detail, and few studies have been performed to discover inhibitors and regulators of GSS activity, which remains an area of active research that will help explore GSS as a possible therapeutic target in cancer cells.

Besides induction by common stressors like free radicals, peroxides, lipid peroxides, and heavy metals, increased GSH production can also be a byproduct of cancer cell metabolic reprogramming ([@bib13]). Oncogenic PI3K signaling has been recently shown to stimulate GSH production in breast cancer cells ([@bib39]) specifically for tumor samples with mutations in this pathway. Additionally, in *MYCN*-amplified neuroblastomas and c-Myc--overexpressing Burkitt's lymphomas, oncogenic Myc regulates the expression of amino acid transporters, which in turn modulate the availability of glutamine, which is the precursor of GSH synthesis. Moreover, if the cells encounter reduced amounts of cysteine, a unique cell death program known as ferroptosis is triggered. Ferroptosis is also triggered by the loss of GSH peroxidase 4 (GPX4), which leads to the accumulation of lipid peroxides ([@bib70]; [@bib72]). Here GSH acts as a cofactor of GPX4; therefore, modulation of amino acid availability and in turn GSH production becomes an important factor for this form of cell death. GSH is also one of the most overrepresented metabolites in ccRCC, lung cancer, and melanoma patient samples relative to normal tissues ([@bib17]; [@bib37]; [@bib23]). Its increased levels are correlated with patients who relapsed after surgical removal of the primary tumor ([@bib23]). In accordance with the data discussed earlier stating increased GSH levels found in cancers, BSO (commonly used as a synthetic inhibitor of GSH production) confers increased sensitivity to chemotherapeutics in myeloma and neck cancers ([@bib61]). Several other drugs known to reduce cellular GSH levels are currently being used in clinical trials to improve efficacy of targeted therapy; for example, disulfiram induces melanoma cell apoptosis by shifting the ratio of GSH/GSSG toward its oxidized state and is now being used in phase I/II clinical research in metastatic melanoma ([@bib8]). Similarly, arsenic trioxide chemotherapeutics combined with agents that deplete cellular GSH have been approved for the treatment of nonacute promyelocytic leukemia ([@bib65]). Therefore, modulating levels of GSH by inhibiting different steps of its de novo biosynthesis is a viable option either to increase the sensitivity of tumor cells to chemotherapeutics or for other targeted therapy.

γ Glutamyl cycle in cancer progression and therapeutic resistance {#s05}
=================================================================

γ Glutamyl transferase (GGT) is a membrane-bound enzyme that catalyzes the degradation of extracellular GSH, favoring production of constituent glutamate and cysteine, needed for the synthesis of intracellular GSH ([Fig. 3](#fig3){ref-type="fig"}). This pathway, also known as the γ glutamyl cycle ([@bib65]), is an alternative to the de novo biosynthetic pathway and plays an important role in maintaining intracellular GSH and cysteine ([@bib73]). GGT levels are significantly up-regulated under oxidative stress, especially in highly metabolic cancer cells ([@bib42]; [@bib1]). GGT depletion in mice results in glutathionuria and cysteine deficiency because of decreased tissue GSH. These phenotypes can be rescued by addition of NAC treatment ([@bib74]). NAC acts as a source of external cysteine, implicating cysteine as a rate-limiting amino acid in this context ([@bib74]).

![**Steps of GSH production and utilization.** GGT is a membrane-bound enzyme that catalyzes the degradation of extracellular GSH, favoring the production of constituent amino acids for the synthesis of intracellular GSH. It also catalyzes the transfer of the glutamyl moiety of GSH, linked through the glutamate γ-carboxylic acid, to acceptor molecules including amino acids and peptides. Other steps of regulation include the expression levels of transporters of glutamate (ASCT2) and cystine (xCT).](JCB_201804161_Fig3){#fig3}

GGT is a heterodimeric glycoprotein consisting of two subunits, where molecular masses of the two chains are between 38 and 72 kD for the large subunit and 20 and 66 kD for the small subunit ([@bib63]). These variations are explained by differential protein glycosylation on seven distinct N-linked glycosylation sites ([@bib10]). GGT is most commonly expressed on the luminal surfaces of secretory cells, particularly in the bile ducts and renal proximal tubules ([@bib10]). Previous research has reported that GGT is dysregulated in several tumor types, namely, ovary, colon, liver, astrocytic glioma, soft tissue sarcoma, melanoma, and leukemia ([@bib9]).

GGT also catalyzes the transfer of the GSH glutamyl moiety, linked through the glutamate γ-carboxylic acid, to acceptor molecules like amino acids and peptides ([Fig. 3](#fig3){ref-type="fig"}). Cisplatin, a common chemotherapeutic, forms adducts with cysteinyl-glycine, a byproduct of GGT activity, much faster than with GSH ([@bib51]; [@bib9]). Therefore, high GGT levels also correlate with therapeutic resistance and worse prognosis in breast cancer and sarcoma patients. TCGA analysis revealed that increased *GGT* is found in ccRCC tumor patient samples compared with adjacent normal tissues, and its expression in the serum of patients is correlated with worse survival rates ([@bib6]; [@bib25]). GGT is also an important enzyme in the detoxifying renal mercapturic acid pathway ([@bib74]). Cisplatin is metabolized to a nephrotoxin when cleaved by GGT1 through this pathway, which can be inhibited by GGT knockdown ([@bib73]). Therefore, GGT1 is also overexpressed in cancer cells selected for resistance to alkylating agents or prooxidant therapeutics such as melphalan, oxaliplatin, and cisplatin.

GGT inhibition represents a novel approach to reduce intracellular GSH levels as a means of sensitizing them to different chemotherapeutics. The most common approach is the use of glutamate analogues like acivin, L azaserine, 6-diazo-5-oxo-[l]{.smallcaps}-norleucine, and boronate derivatives ([@bib63]). However, high toxicity is seen in human patients. Novel classes of noncompetitive inhibitors like OU749, which have low toxicity, can also be used to make the cancer cells sensitive to therapy by lowering the GSH and cysteine availability ([@bib9]).

Regulation of GSH levels by modulating precursor amino acids availability in cancer cells {#s06}
=========================================================================================

Cysteine is a nonessential amino acid for protein synthesis, which stabilizes extracellular proteins by forming intraprotein disulfide bonds. Additionally, cysteine is commonly present in protease metal-binding enzymatic active sites ([@bib19]). Multiple cellular pathways contribute to cysteine production. Apart from the γ glutamyl cycle discussed above, another source of cysteine is via transsulfuration of amino acid substrates. Methionine is converted to S-adenosyl methionine (SAM) by the enzyme methionine adenosyltransferase ([@bib44]), which is then hydrolyzed to homocysteine and converted to cystathionine by two pyridoxal phosphate--dependent enzymes. This can then be cleaved to produce α-ketobutyrate and cysteine in subsequent reactions ([@bib35]). Metabolomic analyses of ccRCC tumors reveal increased amounts of serine, homocysteine, SAM, and S-adenosyl homocysteine (SAH) in low-stage tumors ([@bib37]; [@bib23]) compared with controls. High-stage or more aggressive tumors show increased accumulation of α-hydroxybutyrate and products of methionine metabolism, i.e., SAH, SAM, and homocysteine ([@bib23]). These data indicate that there is preference for cysteine synthesis in early as well as late stage/aggressive ccRCC through a transsulfuration pathway.

Cysteine is also taken up from the tumor microenvironment by a sodium-independent cystine--glutamate antiporter that is chloride dependent, known as system Xc- or xCT, and encoded by the gene *SLC7A11* ([@bib59]). This transporter consists of light (xCT) and heavy (4F2) chains, linked by disulfide bridges. The light xCT chain also has 12 transmembrane domains and primarily imports cystine, the oxidized dimeric form of cysteine, in exchange for glutamate, contributing to tumor growth ([@bib40]). Therefore, besides the biosynthetic pathway, tumor cells modulate cysteine levels to regulate its availability for GSH production as will be discussed.

SLC7A11 is not required for normal mouse development but has been shown to be important for the survival of prostate, breast, kidney, and colon cancer cells ([@bib35]). Moreover, perturbation of xCT levels in these cancers increases their sensitivity to chemotherapeutics, making it an appealing target for combinatorial therapy ([@bib40]). Of note, cancer stem cells have been shown to up-regulate xCT levels, which increase intracellular GSH accumulation ([@bib36]). Sulfasalazine and erastin are the two most commonly used inhibitors of SLC7A11 and can be used as therapeutics to increase sensitivity to other agents ([@bib36]). These compounds induce a specific type of cell death, called ferroptosis ([@bib70]), a nonapoptotic, peroxidation-driven mechanism dependent on cellular iron availability ([@bib15]; [@bib72]). Suppression of cysteine desulfurase (NFS1) induces an iron starvation response, which can trigger this kind of cell death when exposed to ROS ([@bib2]). Similarly, sulfasalazine also induces ferroptosis in diffuse large B cell lymphoma, which exhibits low expression of this cysteine transporter system ([@bib20]). Finally, p53 suppresses *xCT* expression, indicating that xCT inhibitors could be effectively used to limit growth of p53 WT tumors ([@bib30]).

Besides cysteine, other amino acids like glutamine, glutamate, and glycine are also important in cell growth and GSH synthesis. Glutamine availability broadly impacts GSH production by three different mechanisms. First, glutamine is the primary source of glutamate, producing glutamate via two isozymes, glutaminase 1 and 2 (GLS1 and GLS2; [@bib72]; [@bib75]). GLS activity is tightly regulated to maintain appropriate amounts of intracellular glutamate for GSH production. Glutamine can also be transported by several different amino acid transporter systems. Among these, solute carrier family 1, member 5 (SLC1A5/ASCT2), is the most commonly overexpressed transporter protein in different human cancer cells addicted to excess extracellular glutamine ([@bib71]). Glutamine, and consequently GSH levels, is reduced in cells with low ASCT2 expression, along with decreased GLS1 and GLS2. Interestingly, this system is also regulated by c-Myc in prostate cancer and lymphoma cells ([@bib71]; [@bib75]). Second, glutamine contributes to the maintenance of GSH in its reduced form by supporting the production of NADPH through malic acid regulation ([@bib75]). This NADPH is crucial for the conversion of GSSG to GSH as discussed earlier. Third, the xCT transporter system described previously is also dependent on glutamate availability to the cells. Here, one molecule of glutamate is exchanged for every molecule of cysteine taken in. Collectively, abundances of glutamine and glutamate are crucial for the maintenance of proper cellular GSH ([@bib75]).

Glycine is another critical amino acid required for GSH production and maintenance of other metabolic processes, like purine biosynthesis in rapidly dividing cancer cells. Restricting the levels of serine and glycine reduced the levels of GSH synthesis and increased ROS in cancer cells in vitro. Serine can also be produced through transsulfuration pathway in some cases. In tumors where this pathway is interrupted, an increased accumulation of 3-phosphoglycerate has been detected ([@bib41]). Interestingly, glycine uptake and catabolism promote tumorigenesis and malignancy, suggesting that glycine metabolism could also be a target for therapeutic intervention ([@bib28]). By assessing variations in the levels of \>200 metabolites in the NCI-60 cell line series, both glycine consumption and expression of enzymes in the mitochondrial glycine biosynthetic pathway (but not the corresponding cytosolic enzymes) were found to correlate with cancer cell proliferation rates. This indicates that they might be dependent on GSH for their growth and survival. However, these notions need to be studied in more detail in the future ([@bib28]).

Role of NRF2 and KEAP1 in the regulation of GSH abundance {#s07}
=========================================================

NRF2 is regarded as a major contributor to cell survival and redox balance and is regulated by KEAP1, an adapter protein of Cullin 3 (Cul3) containing E3 ubiquitin ligases. Under basal conditions, KEAP1 binds to specific NRF2 motifs, leading to ubiquitination and subsequent NRF2 degradation ([@bib31]). However, under oxidative stress, cysteine residues on KEAP1 are modified, altering its conformation and disrupting its association with NRF2 and subsequent NRF2 stabilization ([@bib62]). Free NRF2 then translocates to the nucleus, where it binds to antioxidant response elements throughout the genome, to activate downstream effector genes ([@bib22]; [@bib62]). In addition to the KEAP1-dependent pathway, NRF2 degradation is regulated by an additional β-TrCP--dependent degradation pathway, via NRF2 phosphorylation by GSK3 in a PI3K-dependent manner ([@bib24]). Phosphorylated NRF2 is then ubiquitinated by β-TrCP and degraded by the proteasome. In accordance with phenomena described above, simultaneous inactivation of phosphatase and tensin homolog (PTEN; a phosphoinositide 3-phosphatase) and KEAP1 has an additive effect on NRF2 activity ([@bib62]). The antioxidant response genes activated by NRF2 include genes responsible for (a) regulating GSH synthesis and metabolism, (b) antioxidant proteins like GPX, (c) drug-metabolizing enzymes and xenobiotic transporters, and (d) additional stress response proteins ([@bib29]).

Recent studies have demonstrated that NRF2 promotes the survival of not only normal cells but also their malignant counterparts by increasing the expression of several cytoprotective genes ([@bib47]; [@bib31]; [@bib56]; [@bib62]). *NRF2* and *KEAP1* are among the most frequently mutated genes in squamous cell lung cancers and hepatocellular carcinoma. Mutations in *KEAP1* or *NRF2* lead to metabolic rewiring of tumors toward increased glutamine consumption for GSH synthesis ([@bib54]; [@bib56]). Several mechanisms appear to be responsible for increased NRF2 activity in cancers: somatic mutations in *KEAP1*, *CUL3*, or *NRF2*; epigenetic silencing of *KEAP*; transcriptional *NRF2* up-regulation through oncogene-dependent signaling and modification of KEAP1 by metabolic alterations ([@bib31]); and cysteine modification of KEAP1, leading to NRF2 accumulation. *NRF2* and *KEAP1* somatic mutations have been shown to correlate with poor clinical outcome in several cancers such as renal cell carcinoma and pancreatic cancer ([@bib29]; [@bib31]). NRF2 activation can also result in increased xCT accumulation, which eventually results in high GSH dependency of the affected cells.

Considering the important role NRF2 plays in tumor progression, thorough screens to identify potent NRF2 inhibitors have been performed by different groups. Small molecule inhibitors ML385 and CPUY192018 are the two compounds that have been discovered recently ([@bib45]). The plant-derived compound brusatol also decreases NRF2 protein levels ([@bib52]), and use of any of these compounds improves sensitivity to chemotherapeutics such as cisplatin and gemcitabine. Other small molecules that suppress NRF2 activity are retinoic acid, ascorbic acid, and luteolin ([@bib67]; [@bib18]). However, they are not very specific in their actions and also can promote NRF2 activity in some instances. Therefore, more thorough research needs to be performed to discover effective and highly selective inhibitors of NRF2 activity ([@bib47]).

GST and its role in therapeutic resistance {#s08}
==========================================

GST is primarily responsible for binding to xenobiotics and GSH, forming conjugates that are then secreted extracellularly ([@bib73]; [@bib17]; [@bib43]). There are primarily three types of GSTs: cytosolic, mitochondrial, and nuclear. Specifically, these GSTs bind both the substrate and GSH at different sites of the enzyme, eventually activating the thiol group of GSH to enable nucleophilic attack on the substrate. Compounds that are targeted in this manner include pesticides, herbicides, carcinogens, and even certain chemotherapeutics. Hence, GST overexpression is known to be one of the underlying reasons for therapeutic resistance in some cancers ([@bib17]). The GSH--GST--drug conjugate formed is effluxed out of the cell via multiple resistance-associated protein (MRP1) transporters. MRP1 accumulation is often increased in drug-resistant cancer cells along with GST. Several inhibitors of GSTs have been developed to improve the response of human tumors to chemotherapeutics. Ethacraplatin, ethacrynic acid, and its analogues are currently being tested for their toxicity and tolerance in patients with invasive bladder cancer ([@bib17]). Collectively, a combination of inhibitors of GSH synthesis and/or its utilization with either chemotherapeutics or targeted treatment might increase the sensitivity of such drugs and provide viable options for patients suffering from therapy-resistant tumors.

Conclusion {#s09}
==========

The literature reviewed in our work indicates that GSH and GSH-related moieties play a significant role in tumor initiation, progression, and drug resistance. Although it has been known for some time that GSH is important in these processes, the distinct role it plays at each step is still being elucidated. Moreover, the interplay between metabolism and the microenvironment and their relationship to tumor GSH levels has not been studied. As discussed in this review, GSH also has antioxidant-independent functions in cancer cells. However, this has only recently begun to be investigated. A better understanding of these pathways and the role of GSH in them should aid the development of mechanism-based GSH inhibitors, which can then be combinatorically used with other drugs to effectively limit tumor growth.
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